Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79226.981.3843%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Ocular Therapeutix Inc

OCULNASDAQ
Trade with Public
Trade with Public
$10.64
N/A
At close: Sep 4, 5:00 PM EST
$10.45
-0.19-1.79%
After Hours: Sep 4, 5:02 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Ocular Therapeutix Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ocular Therapeutix (OCUL).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

2S.Buy
10Buy
Consensus RatingBuy# Analysts12Avg. Consensus PT$23Upside to Avg. PT+117.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 4, 2026Chardan CapitalAndreas ArgyridesMaintainedBuy$23
Jun 25, 2026Chardan CapitalAndreas ArgyridesPT RaiseBuy$21→$23
More with Benzinga EdgeGet Access

Analyst Ratings News

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.
Vandana Singh

PRO
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $25.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $30

Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raises the price target from $24 to $30.
Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target

RBC Capital analyst Lisa Walter reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and maintains $30 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $21 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $21 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved